During the third quarter, Bank Pictet & Cie Europe AG increased its stake in Gilead Sciences by 502.8%, acquiring an additional 12,752 shares to reach a total holding of 15,288 shares valued at approximately $1.7 million. Other major institutions followed suit: Invesco Ltd. added 3.39 million shares (a 33.5% increase) in the second quarter, bringing its total to 13.52 million shares; Sivik Global Healthcare LLC boosted its position by 25% to 50,000 shares; and Lombard Odier Asset Management Switzerland SA grew its stake by 24.6% to 53,312 shares. Overall, 83.67% of Gilead’s outstanding shares are held by institutional investors, underscoring robust confidence from large-scale asset managers.

In its most recent quarterly report, Gilead reported earnings per share of $2.47, outperforming consensus estimates by $0.31, while revenue reached $7.77 billion, topping forecasts by $350 million and reflecting 3.0% year-over-year growth. The company’s return on equity stood at 51.9% and net margin at 27.9%. Gilead reiterated its full-year guidance of $8.05 to $8.25 in EPS, and analysts currently forecast 7.95 EPS for the current fiscal year, signaling steady profitability and cash-flow generation.

Gilead declared a quarterly dividend of $0.79 per share, representing a $3.16 annualized payout and a yield of 2.6%. The payout ratio is approximately 49.0%, demonstrating a balanced approach to returning capital while retaining sufficient cash for R&D and strategic investments. Over the last quarter, insiders sold 136,257 shares totaling $16.9 million, keeping insider ownership at 0.27%.

Analyst sentiment has turned more favorable, with Rothschild & Co Redburn raising its price target by $10 and DBS Bank upgrading to a moderate buy in September. Citigroup lifted its target by $10 and maintained a buy rating, while Scotiabank initiated coverage with a sector outperform rating and a $140 target. Overall, two firms assign a strong buy, twenty-two a buy, and four a hold, resulting in an average consensus of Moderate Buy and an average target of $131.68, reflecting upside potential relative to current trading levels.